Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney  by Doi, Kent et al.
Kidney International, Vol. 65 (2004), pp. 1714–1723
Radical scavenger edaravone developed for clinical use
ameliorates ischemia/reperfusion injury in rat kidney
KENT DOI, YOSHIFUMI SUZUKI, AKIHIDE NAKAO, TOSHIRO FUJITA, and EISEI NOIRI
Department of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan
Radical scavenger edaravone developed for clinical use amelio-
rates ischemia/reperfusion injury in rat kidney.
Background. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-
one) is a potent scavenger of free radicals and has the antioxi-
dant ability to inhibit lipid peroxidation. Its protective effect on
brain ischemia has been shown. This study aimed to elucidate
its possible therapeutic effects on renal oxidative stress in a rat
ischemia/reperfusion model.
Methods. Ischemic acute renal failure was induced by
45-minute clamp of the left renal artery followed by ad-
ministration of edaravone. Renal function and pathologic
findings were examined. The generation of free radicals was
observed by the fluorogenic probe, dichlorodihydrofluorescein
(CM-H2DCFDA), and lipid peroxidation was observed by im-
munochemical staining and Western analysis of 4-hydroxy-2-
hexenal (HHE). The ability of edaravone to reduce in vitro
oxidative stress was investigated using cultured human renal
tubular cells (HKC-8) and the cell viability assay with Alamar
blue.
Results. Edaravone attenuated renal function and patho-
logic findings significantly. The protective effect of edaravone
showed the dose-response was at the same level as that of
dimethylthiourea. In addition, edaravone significantly reduced
the generation of free radicals in the tubular cells indicated by
CM-H2DCFDA. Immunochemical staining and Western analy-
sis of HHE showed significant suppression of lipid peroxidation
in edaravone-treated kidney. In HKC-8 cells loaded with CM-
H2DCFDA, a marked elevation of fluorescence was observed
after exposure to hydrogen peroxide (0.5 mmol/L, for 1 hour),
which was reduced by edaravone. The cell viability assay with
Alamar blue also showed the protective effect of edaravone.
Conclusion. Edaravone ameliorates renal ischemia/
reperfusion injury by scavenging free radicals produced in
renal tubular cells and inhibiting lipid peroxidation.
Reactive oxygen species (ROS) play a role in several
models of experimentally induced ischemia/reperfusion
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injury, such as heart, bowel, liver, brain, and kidney [1].
ROS derive from several different sources, such as mi-
tochondria, xanthine oxidase, prostaglandin H synthase
and lipoxygenase, and neutrophils. Superoxide is gen-
erated when oxygen delivery to the tissue is restored
and the more reactive hydroxyl radical is secondarily
produced from superoxide by Haber-Weiss reaction. Al-
though there are certainly multiple factors in clinical
ischemia/reperfusion injury, the fact that the treatment
with free radical scavengers, such as superoxide dismu-
tase (SOD) and dimethylthiourea (DMTU), attenuates
ischemic acute renal failure (ARF) demonstrates the ma-
jor contribution of ROS at certain stages in ischemic ARF
[2, 3].
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one;
norphenazone, MCI-186) is a potent scavenger of
hydroxyl and peroxyl radicals, and has the antioxidant
ability to inhibit lipid peroxidation. The antioxidant ac-
tivity of edaravone in vitro has been examined in a phos-
phatidylcholine (PC) oxidation system using soybean
unilamellar liposome, in which the oxidation proceeds
by a free radical chain reaction. Edaravone (50 lmol/L)
inhibited the oxidation of PC as efficiently as did
ascorbate (100 lmol/L) and almost as efficiently as did
alpha-tocopherol (2 lmol/L) [4].
In a rat cerebral ischemia model, postischemic treat-
ment with edaravone has been shown to attenuate brain
edema, neurologic score, and hydroxyl radical level mea-
sured by microdialysis technique [5–11]. Edaravone has
also been shown to have a protective effect in a my-
ocardial reperfusion injury model [12, 13]. In 2001, the
Japanese Ministry of Health, Labor and Welfare ap-
proved edaravone for clinical use in treating cerebral
infarction; its neuroprotective effect had been clinically
shown by using magnetic resonance (MR) imaging and
proton MR spectroscopy [14] and by a multicenter, ran-
domized study on acute ischemic stroke in Japan [15].
The purpose of the present study was to elucidate
the possible therapeutic effects of edaravone in a rat
ischemia/reperfusion ARF model. In addition to renal
function, intracellular ROS production and lipid per-
oxidation in renal tubular cells in vivo were examined
1714
Doi et al: Edaravone ameliorates ischemic ARF 1715
by using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydro-
fluorescein diacetate (CM-H2DCFDA), a vital fluoro-
genic probe of oxidative activity, and by using the
antibody to 4-hydroxy-2-hexenal (HHE)-modified pro-
tein, in which HHE is the aldehyde derived from the
oxidative process of polyunsaturated fatty acid. We also
examined the effect of edaravone on decreasing intracel-
lular ROS production and cell viability by using cultured
human renal tubular cells (HKC-8) in vitro.
METHODS
Materials
Edaravone was generously provided by Mitusbishi-
Welpharma (Tokyo, Japan). Edaravone was dissolved in
sodium hydrate and adjusted to pH 7.0 with hydrochlo-
ric acid. CM-H2DCFDA was obtained from Molecular
Probes (Eugene, OR, USA). H2DCFDA is a “dihydro”
derivative of fluorescein and commonly used to detect
the generation of reactive oxygen intermediates because
it is readily oxidized back to the parent dye and thus
serves as a fluorogenic probe [16–18]. CM-H2DCFDA
is a chloromethyl derivative of H2DCFDA, and exhibits
much better retention in live cells than other derivatives.
Dimethylthiourea (DMTU) was obtained from Sigma
Chemical Co. (St. Louis, MO, USA). All other chemi-
cals were purchased from Wako Pure Chemicals (Osaka,
Japan), unless otherwise specified.
Cell culture
The HKC-8 cell line was originally established by
Racusen et al [19] who isolated human renal tubule ep-
ithelial cells and exposed them in culture to a hybrid im-
mortalizing virus, adenovirus 12-SV40. Cultured HKC-8
cells express biochemical and physiologic properties com-
parable to LLC-PK1, opossum kidney (OK), BSC-1, and
HK-2, which are widely used renal proximal tubular cell
lines. In the present study, HKC-8 cells were maintained
in a defined medium (Renal Epithelial Basal Medium)
(Clonetics, San Diego, CA, USA) supplemented with
0.5 mg/L hydrocortisone, 10 lg/L human epidermal
growth factor, 0.5 mg/L adrenaline, 10 mg/L transferrin,
5 mg/L insulin, 6.5 lg/L triiodothyronine, and 5 g/L fetal
bovine serum (FBS) [20].
Surgical procedure
All animal experiments were conducted in accordance
with the “Guide for the Care and Use of Laboratory
Animals” [DHEW Publication No. (NIH) 86–23, revised
1985, Office of Science and Health Reports, DRR/NIH,
Bethesda, MD]. Male Sprague-Dawley rats weighing
120 g were allowed food and water ad libitum. The
animals were anesthetized with a combination of ke-
tamine hydrochloride (11.6 mg/100 g) and xylazine hy-
drochloride (0.77 mg/100 mg). The animals were placed
on a heated surgical pad to maintain rectal temperature
at 37◦C. A 2.5 cm anterior midline incision was made,
the left kidney exposed, and renal ischemia initiated by
clamping the left renal artery. After 45 minutes, the right
pedicle and the right ureter were ligated, and right
nephrectomy was performed. The left artery was sub-
sequently released. In the edaravone-treated group,
edaravone (1, 5, and 10 mg/kg) was administrated
intravenously just after clamp release of the left re-
nal artery and 30 minutes after clamp release. DMTU
was intravenously administered 8 minutes before renal
artery occlusion at a dose of 500 mg/kg [2]. The incision
was closed with 3–0 sutures and surgical staples. Sham-
operated rats served as controls. Kidney specimens for
pathologic analysis were collected 24 hours after surgery.
Renal function was determined at 24, 48, and 72 hours
after the surgery in other experiments.
Measurement of blood urea nitrogen and creatinine
Blood urea nitrogen (BUN) was measured by ul-
traviolet rate assay (Hitachi H-7450) Hitachi, Tokyo,
Japan) and BUN II Reagent Kit (Wako Pure Chemical,
Osaka, Japan). Creatinine was measured by calorimetric
assay (Hitachi H-7450) (Hitachi) and Clinimate Creati-
nine Reagent Kit (Daiichi Chemical, Tokyo, Japan).
Morphologic evaluation of kidneys
Formalin-fixed sections were stained with hematoxylin
and eosin and periodic acid-Schiff, and scored by using
well-established criteria [21].
Western analysis
Harvested kidneys obtained 24 hours after the surgery
were homogenized on ice in a radioimmunoprecipita-
tion assay (RIPA) buffer of the following composition:
0.1% sodium dodecyl sulfate (SDS), 0.5% sodium de-
oxycholate, 1% Igepal CA-630 (Sigma Chemical Co.),
9.1 mmol/L dibasic sodium phosphate, 1.7 mmol/L
monobasic sodium phosphate, and 150 mmol/L NaCl, pH
7.4. Protease inhibitors such as phenylmethylsulfonyl flu-
oride (PMSF) (174 lg/mL) (Sigma Chemical Co.), apro-
tinin (6 lg/mL) (Sigma Chemical Co.), and leupeptin
(10 lg/mL) (Sigma Chemical Co.) were added to the
buffer. The lysates in the sample buffer [3.5% SDS,
100 mmol/L dithiothreitol (DTT), 0.02% bromophenol
blue, 20% glycerol, and 60 mmol/L Tris, pH 6.8] were elec-
trophoretically separated on a 10% polyacrylamide gel.
After transferring proteins from the gel to nitrocellulose
membrane and blocking by a blocking reagent (Block
Ace) (Yukijirushi, Sapporo, Japan), Western blotting was
performed with the antibody to HHE (NOF Corpora-
tion, Tokyo, Japan). The membrane was washed by using
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Tris-buffered saline (TBS) with 0.1% Tween 20 (TBS-T)
for 5 minutes at room temperature with gentle agitation,
and subsequently washed twice with TBS for 10 min-
utes at room temperature. The membrane was incubated
with horseradish peroxidase-conjugated appropriate sec-
ond antibody for 45 minutes at room temperature, and
the membrane was washed with TBS-T for 5 minutes
and with TBS three times for 15 minutes. The chemi-
luminescent signal detection (ECL Plus) (Amersham
Biosciences, Uppsala, Sweden) was preformed using a
LAS-1000 cooled charge-coupled device camera system
(FujiFilm, Tokyo, Japan). The membrane was incubated
at 50◦C for 30 minutes in a stripping buffer (100 mmol/L
2-mercaptoethanol, 2% SDS, and 62.5 mmol/L Tris/HCl,
pH 6.25) to remove all of the probe. The membrane was
washed subsequently with TBS-T twice for 10 minutes,
and blocked with Block Ace for 1 hour at room temper-
ature. The membrane was reprobed with the antibody
to alpha-tubulin (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Densitometric analysis of bands compared
with the density of alpha-tubulin was performed on trip-
licate experiments using National Institutes of Health Im-
age software, version 1.62.
Immunohistochemical analysis
Immunohistochemical staining of 3 lm paraffin sec-
tions was performed using indirect immunohistochemi-
cal techniques. The sections were deparaffinized by 100%
xylene at 50◦C for 10 minutes, 100% xylene at room tem-
perature three times for 3 minutes, and rehydrated in
100% ethanol three times for 3 minutes, 95% ethanol
twice for 3 minutes, and phosphate-buffered saline (PBS)
for 5 minutes. Specimens were autoclaved in 10 mmol/L
citrate-buffered, pH 6.0, preincubated with 0.1% hydro-
gen peroxide for 10 minutes, and blocked by 1 part
of goat serum with 9 parts of PBS. The avidin-biotin
technique in which a biotinylated secondary antibody
reacts with several alkaline phosphatase-conjugated
streptavidin molecules was conducted according to
the manufacturer’s instructions (Dako LSAB2 Kit)
(DakoCytomation, Glostrup, Denmark). Sections were
incubated overnight at 4◦C with primary monoclonal an-
tibodies (2 lg/mL) against HHE. Sections were incu-
bated with the biotinylated antimouse IgG for 10 minutes
and streptavidin conjugated to alkaline phosphatase for
10 minutes subsequently. For the substrate-chromogen
reaction, nitro blue tetrazolium chloride and 5-bromo-4-
chloro-3-indolyl phosphatase, toluidine salt (NBT/BCIP;
Roche, Basel, Switzerland) was used according to the
manufacturer’s protocol. Negative control sections were
subjected to the secondary antibodies only. Mounted
preparations were examined under an Olympus light mi-
croscope (Olympus, Tokyo, Japan).
Fluorescence microscopy
An arterial line was placed in the left jugular artery of
the anesthetized rats and the tip of the arterial line went as
far as the supra diaphragm. CM-H2DCFDA (100 lg) was
injected into the renal circulation over 30 seconds via the
arterial line immediately after clamping the abdominal
aorta below the left renal artery. In the edaravone-treated
group, edaravone (5 mg/kg) was injected simultaneously.
The abdominal arterial clamp was immediately released.
Forty-five minutes after injection, renal ischemia was ini-
tiated by clamping the left renal artery. After 45 minutes,
the right nephrectomy was performed, the left artery was
subsequently released, and edaravone (5 mg/kg) was in-
jected again in the edaravone-treated group. The kid-
ney was harvested 45 minutes after the clamp release
and saved in 10% buffered formalin for paraffin embed-
ding. The 3 lm specimens were examined with a Leica
confocal laser microscope (Leika Mikroskopie, Wetzlar,
Germany).
Fluorescence measurement of intracellular
ROS production
HKC-8 cells, at a density of 5 × 104 per well, were
seeded in a 96-well microplate (Corning, Corning, NY,
USA), and a cell monolayer was obtained after 12 hours’
incubation. To measure intracellular ROS production,
HKC-8 cells were loaded with 10 lmol/L CM-H2DCFDA
for 30 minutes at 37◦C in the dark, after which each exper-
iment was started. Under each experiment, fluorescence
of CM-H2DCFDA was measured on six separate cell
monolayers at an excitation wavelength of 485 nm and
an emission wavelength of 538 nm by a fluorescence mi-
croplate reader (fmax) (Molecular Devices, Sunnyvale,
CA, USA). HKC-8 cells were exposed to hydrogen per-
oxide alone at concentrations of 0.5 mmol/L and in com-
bination with edaravone at concentrations of 10−5 mol/L
and 10−4 mol/L. Experiments were performed for 1 hour,
and data were collected at 5, 10, 20, 45, and 60 minutes.
Cell viability assay
The Alamar blue assay (Biosource International,
Camarillo, CA, USA) is designed for the measurement
of cell viability. It incorporates a fluorometric indicator
based on detection of metabolic activity. The oxidized
form of Alamar blue, which has little intrinsic fluores-
cence, becomes reduced in viable cells, and the reduced
form of the Alamar blue is highly fluorescent. The via-
bility of the cells can be quantified by the extent of this
conversion [22, 23].
HKC-8 cells seeded in a 96-well microplate (Corning)
at a density of 5 × 104 per well were exposed to hydro-
gen peroxide alone at concentrations of 0.5 mmol/L and
in combination with edaravone at concentrations of 10−5
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mol/L and 10−4 mol/L for 8 hours. To examine cell viabil-
ity, HKC-8 cells were loaded with Alamar blue at the final
concentration of 10%. Under each experiment, fluores-
cence of Alamar blue was measured on four separate cell
monolayers at an excitation wavelength of 544 nm and
an emission wavelength of 590 nm by a fluorescence mi-
croplate reader (fmax). The cell viability was calculated
as the ratio of fluorescence intensity in treated cells to
that of untreated cells.
Statistical analysis
The results are expressed as the mean ± SEM. The
differences among experimental groups were detected
by one-way analysis of variance (ANOVA) using Bon-
ferroni’s post hoc analysis. P < 0.05 was considered
significant.
RESULTS
In vivo effect of edaravone in renal ischemia/
reperfusion injury
Ischemic ARF in the rat was initiated by 45-minute
clamp of the left renal artery. The right nephrectomy
was performed followed by the clamp release. BUN and
serum creatinine were measured at 24, 48, and 72 hours
after the surgery. The measurement at 24 hours after
surgery showed significant elevation of BUN and cre-
atinine in the control ischemia group compared with
that of sham-operated animals, as follows: BUN 127.3 ±
13.6 mg/dL (N = 9), creatinine 2.09 ± 0.20 mg/dL (N = 9)
versus BUN 14.5 ± 1.7 mg/dL (N = 5), creatinine 0.32 ±
0.2 mg/dL (N = 5), P < 0.01 (Fig. 1). In the edaravone-
treated group, treatment at the doses of 5 mg/kg and
10 mg/kg attenuated renal dysfunction significantly, com-
pared to the control ischemia group [5 mg/kg BUN 57.3 ±
18.7 mg/dL (N = 6, P < 0.05 versus control ischemia
group), creatinine 0.71 ± 0.21 mg/dL (N = 6, P < 0.01
versus control ischemia group); 10 mg/kg BUN 54.3 ±
10.0 mg/dL (N = 6, P < 0.01 versus control ischemia
group), creatinine 0.86 ± 0.14 mg/dL (N = 6, P < 0.01
versus control ischemia group)]. There was no significant
difference between these two groups and the protective
effect was at the same level as that of DMTU [BUN
48.1 ± 13.8 mg/dL (N = 6, P < 0.01 versus control is-
chemia group), creatinine 0.81 ± 0.25 mg/dL (N = 6,
P < 0.01 versus control ischemia group)]. The treatment
by edaravone at the dose of 1 mg/kg did not improve
renal function [BUN 100.2 ± 16.4 mg/dL (N = 6, not sig-
nificant versus control ischemia group), creatinine 2.01 ±
0.35 mg/dL (N = 6, not significant versus control ischemia
group)].
To determine whether edaravone only retarded the on-
set of renal injury, we examined the time course of the
drug’s effect. All the animals treated by edaravone at the
0
50
100
150
BU
N,
 m
g/
dL
Cr
,
 
m
g/
dL
A
(N = 9) (N = 6)
(N = 6) (N = 6) (N = 6)
(N = 5)
*
**
**
**
0
1
2
Is
ch
em
ia
Ed
ar
av
on
e
1 
m
g/
kg
Ed
ar
av
on
e
5 
m
g/
kg
Ed
ar
av
on
e
10
 m
g/
kg
D
M
TU
Sh
am
**
**
**
**
B
Fig. 1. Blood urea nitrogen (BUN) (A), serum creatinine (Cr) (B) in
rats subjected to 45-minute ischemia 24 hours after surgery. Ischemia,
control ischemia group; Edaravone, edaravone-treated groups; DMTU,
dimethylthiourea-treated group; Sham, sham-operated group. ∗P <0.05
versus control ischemia group; ∗∗P < 0.01 versus control ischemia group.
dose of 5 mg/kg and 10 mg/kg and DMTU survived for
72 hours after the surgery. On the other hand, only three
(33.3%) of nine rats in the control ischemia group and
three (50%) of six rats treated by edaravone at the dose
of 1 mg/kg survived. As shown in Figure 2, the protec-
tive effect of edaravone was demonstrated even 72 hours
after surgery (Fig. 2).
Kidney specimens were collected 24 hours after the
surgery in the other experiments. The levels of BUN
and creatinine examined at sacrifice were nearly equal to
those of the animals described above, which were sacri-
ficed animals 72 hours after the surgery (data not shown).
Morphologic analysis performed 24 hours after surgery
demonstrated that the acute tubular necrosis scoring rep-
resenting the tubular damage was significantly milder in
the edaravone-treated group than in the control ischemia
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Fig. 2. Time-course of serum creatinine (Cr) showing the continuous
protective effect of edaravone. All the animals treated by edaravone at
the doses of 5 mg/kg and 10 mg/kg and by dimethylthiourea (DMTU)
survived for 72 hours after surgery. However, only three (33.3%) of
nine rats in the control ischemia group and three (50%) of six rats
treated by edaravone at the dose of 1 mg/kg survived for 72 hours after
surgery. The analysis was performed only on animals that survived at the
examination of renal function. Symbols are: () control ischemia; ()
edaravone 1 mg/kg; () edaravone 5 mg/kg; () edaravone 10 mg/kg;
and () DMTU.
group (P < 0.05). Histologic scoring showed significant
difference especially in the score of tubular necrosis, casts
formation, interstitial edema, and loss of brush border
(Fig. 3A and D).
Detection of intracellular ROS by CM-H2DCFDA
The fluorogenic probe of intracellular ROS produc-
tion, CM-H2DCFDA, was preinjected followed by renal
ischemia for 45 minutes. Forty-five minutes after clamp
release, the kidneys were harvested and the paraffinized
sections were examined with a confocal laser microscope.
In the control ischemia group, increased fluorescence was
observed in the tubular epithelial cells, and the injection
of edaravone remarkably diminished the fluorescence.
No fluorescence was found in the sham-operated group.
The increased fluorescence was distributed with cytoplas-
mic staining in proximal tubular cells (Fig. 3B).
Lipid peroxidation in renal ischemia/reperfusion
injury in rats
ROS damaged the tissue by the propagation of lipid
peroxidation. Antibody to HHE, produced in the per-
oxidative metabolism of omega-3 polyunsaturated fatty
acids in cell membrane, is one of the specific mark-
ers to detect lipid peroxidation. Kidney specimens were
collected 24 hours after the surgery. Immunohisto-
chemical analysis using antibody against HHE-modified
proteins showed cytoplasmic staining in renal proximal
tubular cells (Fig. 3C). Immunohistochemical staining of
HHE was virtually diminished in the edaravone-treated
group, as shown in the fluorescence microscopy using
CM-H2DCFDA.
Lipid peroxidation was quantified in kidney ho-
mogenates by Western analysis. In the control-ischemia
group, kidney homogenates showed a higher intensity of
immunoreactive bands of HHE-modified proteins com-
pared with those from the edaravone group and sham-
operated group (Fig. 4).
In vitro effect of edaravone in cultured renal tubular cells
To determine whether edaravone would diminish ROS
production in renal tubular cells in vitro, HKC-8 cells
were incubated with CM-H2DCFDA followed by expo-
sure to hydrogen peroxide with or without edaravone. As
shown in Figures 5 and 6, edaravone exhibited dose- and
time-dependent decreases in fluorescence. ROS produc-
tion in renal tubular cells decreased significantly by co-
incubation with edaravone from the time of 20 minutes
after exposure to hydrogen peroxide, and the suppres-
sion of ROS by edaravone lasted until 60 minutes after
exposure, at least.
The effect of scavenging ROS produced in renal tubu-
lar cells in vitro was examined by means of the cell viabil-
ity assay with Alamar blue. Cell viability was significantly
higher in the treatment group at the concentration of 10−4
mol/L than in the treatment group at the concentration
of 10−5 mol/L and control group. The effect of edaravone
appeared from the time of 2 hours and lasted 8 hours after
exposure.
DISCUSSION
In this study, we demonstrated that the administration
of the novel radical scavenger, edaravone, attenuates is-
chemia/reperfusion injury in the rat kidney by scaveng-
ing intracellular ROS in renal tubular cells and inhibiting
lipid peroxidation in cell membrane. We also showed that
edaravone reduces intracellular ROS production and had
a protective effect against oxidative stress in cultured hu-
man renal tubular HKC-8 cells in vitro.
Scavengers such as SOD, DMTU, tempol, and ebse-
len, as well as inhibitors of ROS production such as al-
lopurinol, have been reported to protect against ischemic
ARF [2, 24, 25]. These data confirm the important role
of ROS in ischemic ARF. We have recently reported the
significance of nitrosative and oxidative stress in renal is-
chemia/reperfusion [25], focusing on peroxynitrite which
arises from the reaction of nitric oxide with superoxide. It
was demonstrated that hydroxyl radicals were produced
at the reaction of decomposition of peroxynitrite in vitro
[26, 27], and hydroxyl radicals are expected as the tar-
get of intervention. However, most of the hydroxyl radi-
cal scavengers are not clinically available. Edaravone has
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Fig. 3. Histologic findings. Findings stained with hematoxylin-eosin (A), fluorescence microscopy detecting reactive oxygen species (ROS) by
dichlorodihydrofluorescein (CM-H2DCFDA) (B), immunohistochemistry using antibody to 4-hydroxy-2-hexenal (HHE)-modified proteins (C),
and histologic scoring of the intensity of ischemic acute renal failure (D). ATN, acute tubular necrosis; sham, sham-operated group; ischemia, control
ischemia group; edaravone, edaravone-treated group. ∗P < 0.05 versus control ischemia; ∗∗P < 0.01 versus control ischemia.
recently been approved in Japan for clinical use in the
treatment of cerebral infarction.
Edaravone scavenges hydroxyl and peroxyl radicals.
Hydroxyl radicals initiate the chain oxidation of lipid
by abstracting a hydrogen atom from a polyunsaturated
fatty acid of membrane phospholipids and producing per-
oxyl radicals. Peroxyl radicals remove hydrogen atoms
from other lipids, generating a chain reaction and thus
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propagating lipid peroxidation [28]. In the study by Ya-
mamoto et al [4], the chain oxidation of lipid was inhibited
by edaravone as efficiently as ascorbate (100 lmol/L) and
almost as efficiently as alpha-tocopherol (2 lmol/L) in a
PC oxidation system using soybean unilamellar liposome.
Other in vitro studies showed that edaravone had a pre-
ventive effect on 15-hydroperoxyeicosatetraenoic acid
(HPETE)-induced oxidative injury to cultured bovine
aortic endothelial cells [29], and that edaravone sup-
pressed the decrease of reduced cytochrome c in the xan-
thine oxidase/hypoxanthine system [30]. So far, in terms
of in vivo renal studies, Masaki et al [31] showed the
protective effect of edaravone on cold ischemic kidney,
and Sueishi et al [32] showed the protection by edar-
avone against cisplatin-induced nephrotoxicity. They also
demonstrated that the decrease of glutathione in renal tis-
sue by cisplatin was completely recovered by edaravone.
Both models are considered to be exaggerated by free
radicals. In addition to the kidney model, edaravone has
been shown to have protective effects in the rat cerebral
ischemia model [5–11] and in the myocardial reperfusion
model [12, 13].
In this study, we demonstrated the protective effect
of edaravone on warm renal ischemia-reperfusion in-
jury. The effect was dose-dependent and at the same
level of DMTU, which has been shown to be a strong
hydroxyl radical scavenger [2]. BUN and creatinine in
the edaravone groups and DMTU group were higher
compared with sham-operated animals, although there
was no significant difference. These findings indicated
that other factors might be responsible for the injury,
such as neutrophil migration by the activity of various
chemoattractants [33] and T-cell activation [34] in the rat
ischemia/reperfusion injury model. No significant differ-
ence was found in the attenuation of renal function be-
tween treatment at the doses of 5 mg/kg and 10 mg/kg,
which showed that there is a ceiling effect.
Our findings also demonstrate that there was no ele-
vation of BUN and creatinine at 48 and 72 hours after
surgery in the group treated with edaravone at these two
doses. Edaravone scavenges not only hydroxyl radicals,
which react to other molecules rapidly but peroxyl rad-
icals, which cause a chain reaction of lipid peroxidation
at the cellular membrane. Therefore, the effect of edar-
avone might continue even after the reperfusion.
In the control ischemia group, some of the animals sur-
vived 24 hours after the surgery and subsequently died 48
to 72 hours later. In the model of rat ischemia/reperfusion
injury used by other researchers [2, 33], animals survived
for 72 hours after surgery. This difference may well be due
to the fact that we used relatively smaller rats (weight,
120 g) for this study compared with the sizes of rats used
by the others.
Our present study also demonstrated—for the first
time, to our knowledge—that treatment with edaravone
decreased ROS production in renal tubular cells in vivo
and in vitro, and that edaravone reduced lipid peroxida-
tion in renal tubular cells in vivo. These observations are
consistent with the observation of Paller and Neumann
[35] that ROS were produced mainly by renal tubular
cells and caused lipid peroxidation.
ROS production shown by CM-H2DCFDA in vivo oc-
curred in tubular cells, which become necrotic in ischemic
ARF. Therefore, we measured ROS production in vitro
by using HKC-8 cells and hydrogen peroxide at the con-
centration of 0.5 mmol/L. While a low degree of oxida-
tive stress can trigger apoptosis, higher levels of hydrogen
peroxide above 0.2 mmol/L will cause necrosis [36, 37].
Edaravone showed a dose- and time-dependent effect in
scavenging ROS. We then examined the protective ef-
fect of edaravone on cellular viability by using Alamar
blue, which has been used for monitoring cell growth and
viability, especially in examining toxicity [22, 23]. The de-
crease of cell viability was reduced by edaravone at the
concentration of 10−4 mol/L. The results were consistent
with the result obtained by CM-H2DCFDA assay.
ROS cause cellular injury by attacking membranes
through peroxidation of polyunsaturated fatty acids.
Peroxidations of lipid occur in plasma membrane
and subcellular membranes such as mitochondrial and
lysosomal membranes. Lipid peroxidation alters both
membrane structure and function by causing increased
membrane permeability, impairment of membrane-
bound ion pumps, loss of transport functions, impairment
of oxidative phosphorylation at mitochondria, and leak-
age of hydrolytic enzymes from lysosome [2, 5, 38].
Edaravone reduced lipid peroxidation, as shown by
immunohistochemical staining and Western analysis us-
ing monoclonal antibody to HHE-modified protein.
HHE is one of the major aldehyde products of lipid
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Fig. 4. Western analysis of 4-hydroxy-2-
hexenal (HHE)-modified protein expression.
Sham, sham-operated group; ischemia, con-
trol ischemia group; Edaravone, edaravone-
treated group. Histogram demonstrates the
relative density of bands compared with
alpha-tubulin (N = 3). Representative image
is demonstrated in upper panel.
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Fig. 5. Measurement of intracellular reactive oxygen species (ROS)
production in human renal proximal tubular cells (HKC-8) using the
fluorogenic probe of intracellular ROS production, dichlorodihydroflu-
orescein (CM-H2DCFDA), in vitro. Fluorescence intensity (relative
unit) was measured 60 minutes after exposure to H2O2 at the con-
centration of 0.5 mmol/L. HKC-8 cells were incubated with edaravone
at the concentration of 10−5 mol/L and 10−4 mol/L. ∗P < 0.05 versus
control.
peroxidation, along with acrolein, crotonaldehyde, and
4-hydroxy-2-nonenal (HNE). HHE originates exclu-
sively from phospholipid-bound omega-3 unsaturated
fatty acids such as eicosapentaenoic and docosahex-
aenoic acids, and is one of the most reliable markers of
free-radical-induced lipid peroxidation as well as HNE.
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Fig. 6. Chronological analysis of intracellular reactive oxygen species
(ROS) production in human renal proximal tubular cells (HKC-8) by
dichlorodihydrofluorescein (CM-H2DCFDA) in vitro. Fluorescence in-
tensity (relative unit) was measured in six independent wells in a 96-
well microplate. ∗P < 0.005 versus control. Symbols are: () H2O2 0.5
mmol/L; () edaravone 10−4 mol/L + H2O2 0.5 mmol/L.
Antibodies against HHE-modified proteins have been
successfully used to detect lipid peroxidation in pancre-
atic tissues of the rat [39] and in macrophages infiltrat-
ing the human atherosclerotic plaque in aorta [Yamada
S, personal communication, 2002]. HHE exhibits cy-
topathological effects such as mitochondrial dysfunction
and induction of apoptosis [40–42]. It is quite possible that
HHE-modified protein might be responsible for the
pathophysiology of ischemic ARF.
Takamatsu, Yuki, and Watanabe [43] examined the
drug’s pharmacokinetics by AUC, Cmax, and t1/2 in a
rat brain ischemia model, and found that edaravone at
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Fig. 7. Cell viability assay with Alamar blue. Human renal proximal
tubular cells (HKC-8) loaded with hydrogen peroxide at the concentra-
tion of 0.5 mmol/L were examined. ∗P < 0.05 versus control. Symbols
are: () H2O2 0.5 mmol/L; () edaravone 10−4 mol/L + H2O2 0.5
mmol/L; () edaravone 10−5 mol/L + H2O2 0.5 mmol/L.
the dose of 3 mg/kg was comparable to the effective hu-
man dose obtained in phase I clinical trials in Japan [44].
The estimated concentration of edaravone injected into
animals in this study (1 to 10 mg/kg) was as high as that
of clinically administered doses given to healthy volun-
teers. In our vitro system, the treatment of 10−4 mol/L
was effective and the treatment of 10−5 mol/L was not.
The concentration of 10−5 mol/L (1742 ng/mL) is as high
as that of a clinical dose [43, 44]. On the other hand, the
effective concentration of edaravone in vitro system in
the previous reports were 5 × 10−5 mol/L in a PC oxida-
tion system with unilamellar liposome [4], 10−6 mol/L in
a 15-HPETE-induced oxidative injury to cultured bovine
aortic endothelial cells [29], and 10−3 mol/L in the xan-
thine oxidase/hypoxanthine system [30]. Therefore, there
was not a marked discrepancy between our study and the
previous reports.
The kidney serves as the primary excretion route
of edaravone, with 80% to 90% of the injected dose
excreted as glucuronide in the urine [44], and the prolon-
gation of edaravone clearance in subjects with renal insuf-
ficiency has not yet been investigated. Furthermore, the
pharmacokinetics and the biophysiologic activity of the
major end products of edaravone, such as 4,5-dione and 2-
oxo-3-(phenylhydrazono)-butanoic acid (OPB), are not
clear. Thus, further investigation into the effective and
safe renal dosage for patients with renal dysfunction is
warranted.
CONCLUSION
The present study demonstrated the efficacy of the
radical scavenger, edaravone, to ameliorate ischemia/
reperfusion injury in the rat. Together with the in vitro ob-
servation that edaravone reduced intracellular ROS pro-
duction, it was demonstrated that edaravone scavenges
ROS produced in renal tubular cells and inhibits lipid per-
oxidation of subcellular membranes in vivo. Edaravone
is now approved in Japan for clinical use in the treatment
of cerebral ischemia, and in light of the findings of the
present study and related research, we propose that clin-
ical investigation of its use in renal hypoxia reperfusion
injury is needed.
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